News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Memorial Sloan-Kettering Cancer Center's Dr. Howard Scher Reaffirms Commitment To Lead Phase I Trials For AV Therapeutics' Prostate Cancer Drug



5/7/2014 9:30:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial for its prostate cancer immunotherapy drug, Capridine-ß.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES